Telangana DCA Makes 277 Seizures Since January

Hyderabad: Telangana accounts for over 35% of India’s pharmaceutical production, with Hyderabad earning the moniker ‘Bulk Drug Capital of India’.

The State has seen substantial growth in the pharmaceutical sector over the past few years. This growth, however, has also brought challenges, including a rise in the production and sale of spurious, unauthorised and counterfeit drugs.

Between January and July 2024, the Telangana Drugs Control Administration (DCA) conducted 12,575 inspections; this led to 277 seizures for various violations, 1,963 instances of departmental action, and 51 convictions.

The seizures, included six cases of spurious drugs; 61 cases of overpricing; 98 cases under the Drug and Magic Remedies (Objectionable Advertisements) Act, 1954; 34 cases involving unlicensed medical shops and warehouses; 14 cases of medicines marketed as food products; three cases of unlicensed cosmetics manufacturing; and two cases of production and sale of banned drugs.

According to the DCA, the State has 702 drug manufacturing units, 53 approved drug testing labs, 273 blood centres and 43,023 medical shops.

Some of the major seizure incidents by the DCA include a search in March at Kodad in Suryapet, where a person was found operating an unlicensed medical shop, leading to a seizure of stock worth ₹12.3 lakh. In April, unauthorised drug manufacturing was uncovered at Ovoid Pharmachem in Jeedimetla, Medchal Malkajgiri, leading to seizure of stocks worth ₹23.9 lakh.

Additionally, the DCA targeted clinics run by quacks (unqualified medical practitioners), conducting 59 searches and seizing medicines worth ₹33.16 lakh over the seven-month period.

Related Posts

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

New Delhi: Aurobindo Pharma Ltd on Friday said it has received final approval from the US health regulator to manufacture and market its generic version of glycerol phenylbutyrate oral liquid…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal, Ajinomoto team on ADC development and manufacturing

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Cancer cure must not be hostage to Big Pharma

Cancer cure must not be hostage to Big Pharma

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India